





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/066,801	02/06/2002	Michael Przewosny	148/50871	4473
23911	7590 01/08/2003			
CROWELL & MORING LLP INTELLECTUAL PROPERTY GROUP P.O. BOX 14300			EXAMINER	
			SACKEY, EE	BENEZER O
WASHINGTON, DC 20044-4300			ART UNIT	PAPER NUMBER
			1626	
			DATE MAILED: 01/08/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 10/066,801 Applicant(s)

PRZEWOSNY ET AL.

Examiner

EBENEZER SACKEY

Art Unit **1626**



The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE					
mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.					
- If NO period for reply is specified above, the maximum statutory period will apply	and will expire SIX (6) MONTHS from the mailing date of this communication.				
 Failure to reply within the set or extended period for reply will, by statute, cause Any reply received by the Office later than three months after the mailing date of 	···				
earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on <u>Feb 6, 2</u> 0	002				
	ction is non-final.				
	except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposition of Claims					
4) 💢 Claim(s) <u>1-29</u>	is/are pending in the application.				
4a) Of the above, claim(s)	is/are withdrawn from consideration.				
5) 💢 Claim(s) <u>1-26</u>	is/are allowed.				
6) 💢 Claim(s) 27-29	is/are rejected.				
7)	is/are objected to.				
	are subject to restriction and/or election requirement.				
Application Papers					
9) \square The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/ard	e a) \square accepted or b) \square objected to by the Examiner.				
	drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11) The proposed drawing correction filed on	is: a) □ approved b) □ disapproved by the Examiner.				
If approved, corrected drawings are required in reply	to this Office action.				
12) The oath or declaration is objected to by the Exam	niner.				
Priority under 35 U.S.C. §§ 119 and 120					
13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some* c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have	ve been received in Application No				
application from the International Bure					
*See the attached detailed Office action for a list of the					
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
a) U The translation of the foreign language provisional application has been received.					
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					
					

Application/Control Number: 10/066,801 Page 2

Art Unit: 1626

DETAILED ACTION

Claims 1-29 are pending.

The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1626

Claim Rejections - 35 U.S.C. § 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 28 and 29 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims recite a host of diseases to be treated by the use of compounds of formula (I). It is not believable on its face in view of the contemporary knowledge of the art that one or more related compounds would have the capacity to treat an extraordinary amount of unrelated diseases which require different pathways and mechanisms. The Merck Index lists 10-12 thousand drugs each known to have a single utility. The instantly claimed compounds are capable of the aforementioned diseases require more than routine experimentation. See *In re Angstadt* 190 USPQ, 214, CCPA (1976)

Application/Control Number: 10/066,801 Page 4

Art Unit: 1626

and *In re Bruster* 185, USPQ 152, CCPA (1975). The statue requires at least one capable use in currently available form.

3. Claims 27 and 29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims above refer to "pharmaceutical composition of claim 25." However, claim 25 depends on claim 14, which is directed to a method of preparing compounds of formula (I). Correction is required of the claim dependency.

Claims 1-26 are not rejected over any prior art of record.

U.S.Patent numbers 2,832,790 and 5,554,768 are cited to show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to E. Sackey whose telephone number is (703) 305-6889. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm.

Art Unit: 1626

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane, can be reached on (703) 308-4537. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

EOS

January 6, 2003

Alan Rotman

Supervisory Patent Examiner

aland Rotman

Art Unit 1625, Group 1600

Technology Center 1